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INTRODUCTION 
 Renal transplantation has a better quality of life and improved overall 
survival when compared to dialysis as a modality of management of end stage 
renal disease patients. When compared to patients staying on transplant waiting 
list, renal transplantation is associated with lower risk of mortality, in patients 
with diabetes, with different age group and in different ethnicity. Renal 
transplant outcome has improved over the past few decades, as a result of 
development of new immunosuppressive drugs. The introduction of drugs such 
as mycophenolate mofetil and Tacrolimus has decreased the incidence of acute 
rejection episodes. The reduction in acute rejection episodes has improved the 
short-term renal survival. In spite of advances in prophylaxis and treatment, 
infection remains the major cause of morbidity and mortality in patients with 
renal transplant. Urinary tract infection (UTI) is a common bacterial infection 
in renal transplant recipient10. The majority of infections occur in the first year 
following transplantation. UTI can worsen the graft and patient survival, may 
be associated with increased morbidity and mortality risk in renal transplant 
recipient. A significant percent of patients may develop acute pyelonephritis, 
which is a risk factor for graft deterioration.  
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AIM 
 1. To study the clinical and microbiological profile of urinary tract 
infection in renal transplant recipients. 
 2. To study the risk factors for urinary tract infection in renal transplant 
recipients. 
 3. To study the effect of urinary tract infection on graft function and 
long term graft survival. 
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MATERIALS AND METHODS 
Study design- prospective observational study 
Study population 
  Patients attending renal transplant clinic and those admitted in renal 
transplant ward, Department of Nephrology, Madras Medical College, from 
July 2011 to December 2012, with fever or urinary symptoms in the form of 
dysuria, frequency, urgency suprapubic pain or pain over graft, or fever of 
unknown origin. 
Exclusion criteria  
 Age of the patient less than 16 years 
 Patients who underwent complex urological surgery like illeal conduit in 
the pre transplant period. 
Evaluation  
 Clinical details of the patient were collected including age, sex, live or 
deceased donor, month and year of transplantation, immunosuppressive 
medication, any induction therapy, any delayed graft function, any rejection 
episodes, any cytomegalovirus infection, history of hepatitis C sero status, 
history of diabetes mellitus, previous episodes of urinary tract infection, history 
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of allograft biopsy, calcineurin inhibitor drug levels and antibiotic prophylaxis 
of urinary tract infection. 
  History of duration of bladder catheterization and history of any 
stenting intra operatively and if positive when stent was removed was noted.  
  History of present problem including fever duration, intensity and 
character, vomiting ,loose stools, urinary symptoms like dysuria, frequency, 
hematuria and Oliguria, and urine output both, before start of the illness and 
after the start of the illness were noted. 
All patients underwent  
 Urine analysis 
 Complete hemogram 
 Blood urea, serum creatinine, serum electrolytes 
 Serum bilirubin, serum albumin, globulin and alkaline phosphatase 
 Urine gram stain and culture including fungal 
 Ultrasonogram abdomen including kidney, ureter and bladder  
 Blood culture and sensitivity for enteric and non enteric organism 
 Arterial blood gas analysis in those with sepsis 
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  When complication was suspected, selected patient underwent CT 
abdomen. Those with recurrent urinary tract infection underwent uroflometry 
and when obstruction was suspected ascending urethrogram. Hepatitis C virus 
screening, those with leukopenia during evaluation, cytomegalovirus screening 
was done 
  Urine was collected in a sterile manner to avoid contamination of 
periurethral flora, in the male by retracting the prepuce and in the female by 
separating the labia majora after washing the external genitalia.  
 The clean catch mid stream of urine collected with above precaution 
should be sent to the laboratory immediately and plated on the MacConkey 
agar and Blood agar within 1 hour. If time delay is expected between collection 
and plating the urine is stored in the refrigerator upto 12hours.  
Statistical analysis 
  All data are expressed as mean± standard deviation. Differences in 
categorical variables were compared using fisher’s exact test. The variables 
were compared using student t test. The difference was considered to be 
significant if the P-value was <0.05. Data was analyzed using SPSS software.  
 
 
REVIEW OF LITERATURE 
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RISK FACTORS FOR URINARY TRACT INFECTION (UTI)  
 The incidence of UTI in immunosuppressed solid organ transplant 
recipients other than renal transplant recipients is not increased, when 
compared to non immunosuppressed individual. The incidence of UTI is 
increased in simultaneous kidney-pancreas transplantation with drainage of 
exocrine secretion into the bladder. 
           Ageing  
Female recipient, pre transplant UTI 
Induction agent, Azathioprine based regimen 
Technical complication, allograft trauma (double renal transplant) 
Post operative bladder catheterization, ureteral stent placement 
Structural abnormalities like reflux nephropathy (native kidney), stone 
disease, diabetes 
Neurogenic bladder  
 Deceased donor and malnutrition 
           Basic disease- Glomerulonephritis as a cause of ESRD62 
Net state of immunosuppression  
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  One of the determinants of infection risk after transplant is net state of 
immunosuppression. The risk of infection increases for several months after 
high dose steroid for rejection. Particularly immunomodulatory viruses like 
EBV, CMV, and BKV infection are increased. There is also increased risk for 
bacterial, fungal and parasitic infection after rejection therapy. There is a need 
for surveillance for bacterial and fungal infection post anti-rejection therapy. 
1. Immunosuppressive therapy (current and past) 
2. Underlying immune deficiency (Systemic lupus erythematosis) 
3. Prior therapies (chemotherapy, antimicrobials) 
4. Lymphopenia, Neutropenia 
5. Mucocutaneous barrier integrity (lines, catheters, drains) 
6. Viral coinfection (CMV,HBV, HCV) 
DEFINITIONS 
 Cystitis is defined by clinical manifestation of dysuria, frequency and 
urgency and by the presence of bacteriuria in the absence of symptoms of 
pyelonephritis.                                                           
Pyelonephritis is defined by simultaneous presence of bacteriuria and fever 
with any one of four features 
Pain over the graft 
Lumbar pain 
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Chills 
Lower urinary symptoms- dysuria, frequency, urgency 
Reinfection is defined by a new episode of infection 
 1. with the same organism, with different antibiotic sensitivity pattern 
 2. Isolation of the organism other than one that caused the previous episode 
Recurrence is defined as more than two (≥3) UTI in a twelve months period. 
Relapse is defined as isolation of same bacteria that caused the preceding 
infection, with the same sensitivity pattern, in a culture obtained ≥ 2weeks after 
completing the previous treatment. 
MICROBIOLOGY 
 Gram negative organism - E. coli is the most common organism isolated 
in post transplant UTI. Other organisms include proteus, klebsiella, 
pseudomonas, serratia, citrobacter, acinetobacter and Corynebacterium 
urealyticum.  
Gram positive organism – coagulase-negative staphylococcus, enterococcus 
species 
HOST DEFENCE 
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 Symptomatic infection caused by uropathogenic strain of 
microorganism induces a strong innate immune response, while a limited 
immune response is induced by strains, causing asymptomatic bacteriuria. 
Bacterial adherence to uroepithelial cells and direct stimulation of epithelial 
cells by lipopolysaccharide causes the cytokine elaboration like IL-6 and IL-8.  
 The cytokines cause migration of neutrophils and other inflammatory 
cells to the bladder and kidney, particularly IL-8 released at the mucosal site 
recruit polymorphonuclear leukocytes. Urine IL-6 levels correlate with the 
severity of infection with higher levels occurring in patients with 
pyelonephritis. The polymorphonuclear leukocytes infiltration developing in 
renal tissue in pyelonephritis limits bacterial spread, but also causes tissue 
damage and renal scaring.  
Humoral immunity  
 There is an IgM antibody response to first episode of infection the upper 
UTI particularly against the surface antigens of E. Coli including O antigens, 
type 1 and P fimbriae. In subsequent episodes antibody response is IgG with 
elevated levels correlating with severe renal infection. There are also increased 
urinary levels of IgG and IgA. 
Cell mediated immunity has a less role in the host defence mechanism against 
urinary infection, as evidence by low susceptibility to UTI in HIV infected 
women with very low CD4 counts15.  
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AGENT FACTOR 
 E.coli colonise colon of new born soon after birth. Some of these strains 
colonise periurethral area and enter bladder. Majority of infections are caused 
by Uropathogenic E.coli(UPEC).They possess a variety of virulence factors 
like polysaccharide capsule, adhesins, siderophores and cytotoxins including 
hemolysin, cytotoxic necrotising factor, Secreted Autotrasporter Toxin. Among 
the 4 main phylogenitic groups, B2 &D groups cause more infection than A 
&B163. 
Pathogenicity associated islands (PAIs) are virulence factor rich clusters of 
DNA .These mobile genetic elements contribute to the emergence of 
pathogenic strains from commensal group. 
 Molecular interactions between adhesins on bacterial surface and 
epithelial cell receptors favour tropism. Type I fimbria bind to mannose 
containing glycoprotein via Fim H adhesin. UPEC have 20 times increased 
affinity to uroepithelial cells63. New adhesin P fimbriae is encoded with in 
chromosomal PAIs. The receptor for P fimbriae is gal-gal disaccharide, a 
glycolipid found in renal epithelium. Other fimbrial factors are Dr Adhesin 
family, FIC fimbria and S fimbriae family. 
Prophylaxis  
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 Antimicrobial prophylaxis has decreased the incidence and severity of 
infection in the posttransplant period55. Three general preventive strategies are 
used: (1) vaccination, (2) preemptive or presymptomatic therapy and (3) 
universal prophylaxis including surgical prophylaxis. Universal prophylaxis 
involves giving antimicrobial therapy to all ‘at-risk’ patients for a defined time 
period. The use of trimethoprim-sulphamethoxazole from three months to life 
time is used for prophylaxis of urinary tract infection and PCP pneumonia55. 
The TMP-SMX also covers Toxoplasma gondii, Isospora belli, Cyclospora 
cayetanensis, many Nocardia and Listeria species, in addition to common 
urinary microbes. In the absence of allergy or interstitial nephritis, low dose 
TMP-SMX should be continued. In the one to 6 months period TMP-SMX is 
able to prevent opportunistic infection and urinary infection when the peak 
effect of immunosuppression is noticed. Those patients who are not tolerating 
TMP-SMX, quinolones can be used for preventing urinary tract infection. 
 
NOSOCOMIAL INFECTION   
 Nosocomial infection, is an infection, one acquired by a patient during a 
hospital visit or one developing among hospital staffs, whose development is 
favoured by a hospital environment,. Such infections include fungal and 
bacterial infections and are aggravated by the reduced resistance of individual 
patients. Nosocomial infections include fungal and bacterial infections. 
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Nosocomial infections are aggravated by the reduced resistance of individual 
patients.  
 Nosocomial infections can cause severe pneumonia and infections of the 
bloodstream, urinary tract and other parts of the body. Many types of antibiotic 
resistance are spreading to Gram-negative bacteria that can infect people 
outside the hospital. The nosocomial infections more commonly occurs in the 
urinary tract, surgical site and lungs. One third of nosocomial infections are 
considered preventable.  
  Nosocomial bacteria include MRSA (resistant strain of S. aureus), 
member of Gram-positive bacteria and Acinetobacter (A. baumannii), which is 
Gram-negative and the drug-resistant, Gram-negative Klebsiella pneumoniae. 
Few effective drugs are available for acinetobacter and the bacteria is evolving 
and becoming immune to existing antibiotics, in many cases they are sensitive 
to polymyxin group of drugs only. More than 20% of Klebsiella pneumonia are 
now resistant to virtually all modern antibiotics. The gram-negative bacteria 
can cause severe pneumonia and infections of the urinary tract, bloodstream, 
and other parts of the body. Most common site of involvement is urinary tract, 
followed by lung and surgical site. Nosocomial infections prolong the hospital 
stay by four to five additional days. The nosocomial infections threaten only 
hospitalized patients whose immune systems are weak. The bacteria can 
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survive for a longer time on surfaces in the hospital and enter the body through 
catheters wounds, or ventilators 
Main routes of transmission are direct contact, through droplet, airborne, 
common vehicle and vector borne 
Route Description 
Contact 
transmission 
The most important and frequent mode of transmission of 
nosocomial infections is by direct contact. 
Common vehicle 
transmission 
This applies to microorganisms transmitted by 
contaminated items to the host, such as food, water, 
medications, devices, and equipment. 
Vector borne 
transmission 
This occurs when vectors such as mosquitoes, flies and rats 
transmit microorganisms. 
Contact transmission is divided into two subgroups: direct-contact transmission 
and indirect-contact transmission. 
Factors predisposing to infection  
 1. Poor health- General risks for nosocomial infection are advanced age 
with immunodeficiency and in renal transplant patients with pretransplant 
malnutrition.  
 2.Invasive devices- Patients are colonized with organisms while in 
hospital and on invasive devices, for instance catheters, surgical drains, 
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intubation tubes, and tracheostomy tubes, all bypass the body’s natural lines of 
defence against pathogens and provide an easy entry for microbes.  
  3. Patient therapy- Antimicrobial therapy while removing competitive 
flora, leaves only resistant organisms, recurrent blood transfusion and treatment 
with antacid and immunosuppression treatment undermine the body’s defences. 
CATHETER ASSOCIATED INFECTION 
 Catheter associated infection is defined as the infection occurring in an 
individual whose urinary tract is currently catheterised or who has been 
catheterized within the previous 48 hours. The incidence of bacteriuria in those 
with indwelling bladder catheterization is 3% to 8% per day. Risk factors for 
catheter associated UTI include female gender, microbial colonization of 
drainage bag, diabetes mellitus, positive urethral meatal culture and not 
receiving systemic antimicrobial therapy. Most catheters are latex based which 
is associated with inflammation, urethritis, penile discomfort and stricture 
formation. 
 Organisms causing catheter associated UTI are E. coli, proteus, 
klebsiella, pseudomonas, enterococcus, coagulase-negative staphylococcus, 
serratia citrobater and enterobacter. E. coli is the most common organism 
isolated in about one-third of patients. 
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Pathogenesis- Urinary catheter is an important predisposing factor for 
nosocomial UTI. At the time of insertion the catheter introduces an inoculum 
of bacteria into the bladder. After catheterization residual urine in the bladder is 
increased due to pooling below the catheter bulb. 
      External surface of the catheter- 66% 
Portal of entry of microorganism  
      Via the lumen of the catheter - 34% 
 
Biofilm formation 
 Bacteria attaches to the catheter by using adhesins, to the host cell 
receptors on the catheter surface. Then, they change phenotypically and 
produce exopolysaccharides which cover and protect replicating bacteria, 
forming microcolonies, and ultimately forming mature biofilms. Biofilms 
develop on both inner and outer surface of the urinary catheter. There is 
exchange of genetic material among organism within the biofilm, which 
facilitates the spread of antimicrobial resistance genes. In catheters with 
biofilm, bacteria isolated in urine obtained through the catheter may not reflect 
the bacteria in the bladder urine causing UTI.  
Specimen collection 
 A urine specimen for culture should be obtained prior to starting 
antimicrobial therapy for suspected catheter associated UTI, because of the 
wide spectrum of the possible infecting organism. Specimens for culture are 
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obtained by sampling through the catheter port or if the port is not present, 
puncturing catheter tubing with syringe and needle. Culture specimen should 
not be collected from the drainage bag. In patients with long term 
catheterisation, urine specimen should be obtained after the catheter has been 
replaced. 
Diagnosis 
 Symptoms and signs in patients with indwelling bladder catheterization 
including new onset or worsening fever, rigors, altered mental status, malaise 
or lethargy with no other identified cause; acute hematuria; pelvic pain; pain 
and tenderness over allograft, along with ≥1000 cfu/ml of bacteria in a single 
catheter urine specimen indicates catheter associated UTI. In catheterised 
patients absence of pyuria suggests a diagnosis other than catheter associated 
UTI. Pyuria in the absence of bacteriuria is not diagnostic of catheter 
associated UTI. Unpleasant odour of urine does not indicate bacteriuria in all 
patients. Like-wise not all patients with UTI have unpleasant odour. 
In patients on clean intermittent catheterization ≥ 100 cfu/ml in a catheter urine 
specimen is significant. 
Prevention  
 Indwelling catheters should be inserted using aseptic technique and 
sterile equipment 
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 A closed catheter drainage system with port in the distal part for needle 
aspiration of urine should be used to reduce catheter associated UTI.  
 Systemic antimicrobial therapy before insertireduces catheter associated 
UTI in short term, but should not be given routinely, because of the chance of 
antimicrobial résistance. 
 The most effective way to reduce catheter associated UTI is to remove 
the catheter promptly when it is no longer needed.  
Treatment 
 General measures- antimicrobial resistance is increasing, so 
antimicrobial susceptibility testing is to be done in all bacterial isolates. 
Antimicrobial therapy is to be administered against the specific pathogen 
identified according to the culture result. Initial therapy in critically ill patient 
should be broad spectrum which is to be narrowed after 24 to 48 hours, 
depending on the culture report. Nephrotoxic drugs like aminoglycosides or 
amphotericin to be avoided, if equally effective alternative agents are available. 
When the organism is multidrug resistant one like carbapenem resistant 
klebsiella pneumonia, nephrotoxic drug like intravenous colistin can be used.  
 Drug level should be measured when available like vancomycin, 
aminoglycosides, voriconazole. Reduction of immunosuppression during 
episodes of infection will help in resolution of infection- including decrease in 
mycophenolate mofetil or azathioprine dose or targeting a lower level of 
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calcineurin inhibitor. For those with recurrent infection, there may be a need 
for long term reduction in immunosuppression if it can be done without 
inducing rejection. For patients with neutropenia with fever or symptoms or 
signs of infection, granulocyte colony-stimulating factor is administered to 
increase the neutrophil count. There is no increased incidence of rejection with 
granulocyte colony-stimulating factor. Drugs that can cause leukopenia should 
be discontinued temporarily when there are symptoms or signs of infection in 
leukopenic transplant recipient like Azathioprine, MMF, and valgancyclovir.  
 When the patient has prompt resolution of symptoms, the duration of 
therapy for catheter associated UTI is seven days. When the patient has delayed 
response the duration of therapy is 10 to 14 days irrespective of whether the 
catheter is removed or not.  
URETERAL STENTING 
 Vesicoureteral anastomosis initially was done by transvesical approach 
(Lead better politano technique). Now the technique is end-to-side extravesical 
implantation of the ureter into the anterior wall of the bladder, by modified 
Lich-gregoire technique29. The anastomosis was made between the spatulated 
distal donor ureter and a small bladder mucosal nick. 
 Double-J stent has a straight tube with anchoring J loops at the end. 
Prophylactic stenting of the ureter is being done to avoid major urological 
complication originating from vesicoureteral junction anastomosis. The 
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complications of anastomosis occur during the early post transplant period 
mostly in the first three months. The complications include obstruction, urinary 
leak, necrosis, and stenosis and vesicoureteral reflux30. The ureteric obstruction 
can also be caused by intraluminal obstruction, such as calculi, blood clots, or 
extraluminal compression of blood and lymphatic fluid36, 37. The urological 
complication arises as a result of distal transplant ureteral ischemia or due to 
surgical factors like ureteroneocystostomy techniques and poor graft 
harvesting. These complications cause delayed graft function, increased 
morbidity and may cause graft or patient loss28. Stenting is preferred by most 
transplant surgeons, when the healing process is either expected to be delayed 
or there is an increased risk of urine leak after transplantation 
INDICATION FOR DJ STENTING  
 1. Dry anastomosis: No urine output after implantation of the graft 
 2. Graft kidneys from deceased donors 
 3. Prolonged ischemia time like in deceased donor40 
 4. Abnormal bladder- small bladder, neurogenic bladder, irradiated 
bladder and urethral valve 34 
 5. Those with comorbidities like multiple abdominal surgeries, obesity, 
and previous peritonitis where wound healing is expected to be delayed 
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 6. Precarious ureteric blood supply- Extensive mobilization of donor 
ureter, double ureter, shortened or injured ureter, or accidental dissection of the 
golden triangle. 
Benefits of stenting are simplifying the creation of water tight anastomosis and 
reduced incidence of anatomical kinking.  
 Complications of stenting- are stent migration, irritative bladder 
symptoms like post operative pain and stone formation in the graft kidney after 
transplantation, persistent hematuria, encrustation, breakage, complication 
during removal, forgotten stents, erosion of lumen and importantly post 
operative urinary tract infection25. Stent can also exacerbate long-term 
stricturing of the ureter33.  
 The incidence of UTI is increased not only during stenting period, but 
also after removal of the stents. Stenting can convert what may be a simple 
urinary tract infection to complicated pyelonephritis, and can act as a focus for 
bacterial persistence38. In those who has stenting, there is higher relative risk of 
BK virus allograft nephropathy39. 
 In normal urological practice stenting is advised, since 
ureteroneocystostomy is done on abnormal ureters. Transplantation is a 
procedure where normal ureter is involved in ureteroneocystostomy to a normal 
bladder. Stenting cannot be a substitute for a carefully done 
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ureteroneocystostomy, even when ureter needs to be anastomosed to abnormal 
bladder.  
 Stent can be avoided by tension-free anastomosis and proper care is 
taken for maintaining the ureteric vascularity31. The preservation of the ureteric 
blood supply as maintained by (1) nondissection technique in the golden 
triangle, (2) preservation of lower pole graft vessels during dissection and 
anastomosis, and (3) avoiding dissection close to the periureteric adventitia and 
there by maintaining the ureteric blood supply is essential to avoid transplant 
ureteric ischemia. Stenting should be restricted to difficult ureterovesical 
anastomosis and unfavourable anatomy. The duration of stenting may be 
limited to 3 or 4 weeks to avoid the complication due to stenting33. 
SUPPRESSIVE ANTIMICROBIAL THERAPY 
 Suppressive antimicrobial therapy is indicated in patients with frequent 
and recurrent symptomatic infection  
With underlying genitourinary abnormality that cannot be corrected 
Renal transplant recipient 
Renal failure or those with ureteric stents 
 Stent coated with biofilm contains high concentration of urease 
producing microorganisms particularly proteus species, pseudomonas 
aeruoginosa, klebsiella pneumonia and providencia species. These organisms 
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have the capacity to hydrolyse the urea in the urine to free ammonia, causing 
elevation in local pH facilitating precipitation of minerals, which can block 
urine flow. The organisms growing in biofilms are protected from both 
antimicrobials and host defences. Ultimately relapse of infection occurs in post 
transplant patients. 
 Suppressive antimicrobial therapy involves initial period of full dose 
therapy still negative culture, followed by reduced dose for 12 to twenty four 
weeks. Norfloxacin is the commonly used drug for suppressive prophylaxis. 
ASYMPTOMATIC BACTERIURIA  
Definition  
Women - Asymptomatic bacteriuria is defined as isolation of the same 
organism >10⁵ colony-forming units/ml on two consecutive voided specimens. 
Men – asymptomatic bacteriuria is defined as isolation of one bacterial species 
>10⁵ colony-forming units/ml of clean-catch voided urine specimen, on a 
single occasion, without any symptoms of urinary tract infection.  
 Systemic screening and treatment of asymptomatic bacteriuria in 
patients who have undergone transurethral resection of prostate and in pregnant 
women have been associated with reduction in pyelonephritis. In diabetic 
women treatment of asymptomatic bacteriuria is not useful in preventing 
pyelonephritis or diabetic nephropathy.                                
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The incidence of pyelonephritis was more frequent in patients with 
asymptomatic bacteriuria16. Pyelonephritis episodes were associated with 
rejection in renal transplant recipients. Repeated episodes of asymptomatic 
bacteriuria, even with systemic treatment are an independent risk factor for the 
occurrence of pyelonephritis. 
Treatment 
 Systemic treatment of asymptomatic bacteriuria may reduce the 
incidence of pyelonephritis50. The antibiotics recommended for treatment of 
asymptomatic bacteriuria are 
Ciprofloxacin 250 mg twice daily for 3 days 
Amoxicillin-clavulanate 625 mg 8th hourly for 7 days 
Cefuroxime 250 mg 12th hourly for 7 days  
FUNGAL UTI 
 Fungal infections primarily affect the bladder and kidneys. The most 
common cause is candida species, which are normal commensals in humans. 
The candida species causing UTI are Candida albicans, Candida glabrata, 
Candida tropicalis and Candida parapsilosis. The majority of these infections 
occur within the first two months after transplantation.  
Risk factors  
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1. Prior antibiotic therapy 
2. Urinary tract devices 
3. Diabetes 
4. Urinary tract structural abnormalities 
5. Maintenance Tacrolimus and allograft rejection 
Candida cystitis 
 Usually occurs with presence of urinary catheters and after bacteriuria 
and antibiotic therapy. Candidal and bacterial infection usually occur 
simultaneously51. 
Symptoms 
 Most patients with candiduria are asymptomatic. They may present with 
dysuria, frequency, urgency and suprapubic pain. Hematuria is common and 
may present with pneumaturia due to emphysematous cystitis or symptoms of 
urethral obstruction due to fungal balls in the bladder. 
Diagnosis 
 Ccandida UTI is diagnosed by urine culture. Differentiating candida 
colonisation from infection is difficult. When candiduria is associated with 
pyuria suggesting bladder inflammation, infection can be diagnosed52. 
Candida pyelonephritis 
 Uusually occurs through hematogenous seeding from the 
gastrointestinal tract. Ascending infection can also occur in patients with 
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permanent indwelling bladder catheter and ureteral stents. The major source of 
candidemia in immunosuppressed hospitalised patients is an indwelling 
intravascular catheter. 
Symptoms and signs 
 Due to hematogenous spread most patients lack renal symptoms. They 
may present with antibiotic resistant fever, unexplained graft dysfunction or 
candiduria. They frequently have hematuria and urinary obstruction due to 
fungal ball in the pelvis or ureter. Some patients may have loin pain, fever, 
hypertension due to papillary necrosis or intrarenal or perinephric abscesses. 
They may present with manifestation in other sites like liver, spleen, skin, eyes 
or CNS.  
Diagnosis 
 Identifying the species of candida by culture is necessary and antifungal 
susceptibility to be done in urine culture. Blood cultures for candida are often 
negative. Fever with passage of fungus balls suggests renal infection. Severe 
renal failure is unusual unless there is post renal obstruction. Imaging of 
transplant kidney to rule out collecting system abscess or presence of fungus 
ball is recommended. 
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Treatment  
Systemic prophylaxis of fungal infection is generally not required.  
Fungal colonization of catheters does not require treatment.  
Candiduria should be treated in the following situations: 
1. Asymptomatic patients: with renal allograft and neutropenic patients.  
       IDSA recommend treatment of asymptomatic candiduria with 
Fluconazole 200 mg orally per day for 7 to 14 days or I.V. amphotericin 
B, 0.3 to 1 mg/kg/day for 1 to 7 days. The ecchinocandins achieve low 
urinary concentration not recommended for fungal urinary tract 
infection. Intravesical irrigation of amphotericin B is not useful.  
2. Symptomatic patients 
3. Urinary catheters and stents should be removed if possible 
 Most common antifungal agents used for the treatment of candidemia 
are fluconazole, amphotericin B and caspofungin. Fluconazole is the only azole 
concentrated in the urine, so has important role in the treatment of UTI.  
 Many Candida glabrata strains are resistant to fluconazole. The 
Infectious Disease Society of America recommends to avoid the use of 
fluconazole for the treatment of C. glabrata13. Amphotericin B remains the drug 
of choice, though caspofungin is preferred due to its better safety profile. Oral 
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or intravenous voriconazole has been recommended for disseminated infections 
caused by candida species and in patients refractory to other antifungal 
therapy14. 
Duration of therapy- two weeks of therapy after cultures become negative is 
advised. 
Drug interactions and toxicities of anti-fungal agents 
        Therapeutic drug level monitoring of the primary immunosuppressant 
must be done frequently and dose adjusted to achieve the desired level of the 
drug, both when initiating and discontinuing anti-infective therapy. As 
interaction with ketoconazole is potent, there is a need for reducing the 
cyclosporine dose by 80%. 
Anti fungal 
agent 
Drug interactions or 
toxicities 
Additional information 
Amphotericin B Enhanced nephrotoxicity For invasive fungal 
infection, liposomal 
formulations preferred to 
reduce risk of nephrotoxicity
Clotrimazole 
(topical) 
Increased level of Tacrolimus 
via Cytochrome P4503A4 
inhibition in the gut 
Dose adjustment often 
needed 
Azole antifungals Increased levels of 
Tacrolimus, cyclosporine, 
everolimus and sirolimus via 
Empiric dose adjustment of 
immunosuppressant is 
recommended when 
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Cytochrome P4503A4 
inhibition 
initiating azole therapy 
 
Other invasive fungal infections- may infect the kidneys as part of systemic or 
disseminated fungal infection12. They are Cryptococcus neoformans, 
Aspergillosis, and endemic mycosis like Histoplasma capsulatum, Blastomyces 
dermatitides, Coccidiodes immitis. Infections typically occur in the mid to late 
post transplant period, although some occur within two months of transplant. 
VIRAL UTI 
Adenovirus- is a double stranded DNA virus, usually associated with mild, self 
limiting upper respiratory tract syndromes in immunocompetent children. This 
is followed by asymptomatic latent infection of lymphoid tissue41.  
Major syndromes caused by adenovirus are acute respiratory disease, acute 
hemorrhagic cystitis (serotypes 11 and 21), gastroenteritis, 
pharyngoconjunctiva l fever and epidemic keratoconjunctivitis. 
Risk factors in transplant recipient 
T-cell depleting agents, lymphopenia, prolonged neutropenia, young age and 
graft versus host disease.  
Clinical features  
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 In immunocompromised adenovirus infection present with disseminated 
infection including hemorrhagic cystitis, nephritis, pneumonitis, hepatitis and 
gastroenteritis, present as diarrhoea with dehydration, dyspnoea, dry cough, 
reticulonodular pulmonary infiltrates and elevated transaminases or fever of 
unknown origin42. 
Adenovirus cystitis present with hematuria for less than 3 days, without fever. 
Nephritis present with flank pain and fever. 
Diagnosis  
 Antigen detection by indirect immunofluorescence assays in tissue 
specimens.  
 Polymerase chain reaction used to identify adenovirus on various 
specimens including urine blood and sino-nasal and lung tissue43. 
 Renal- Urine analysis, urine culture both viral and bacterial and 
ultrasonogram to demonstrate enlarged kidneys. Other causes to be ruled out if 
hemorrhagic cystitis does not resolve within 5 days.  
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Renal biopsy 
 Shows non-specific lymphocyte infiltration. Tubular epithelium shows 
viral intranuclear and intracytoplasmic inclusions (smudge cells) with positive 
immunohistochemical staining specific for adenovirus.  
Treatment 
1. Reduction of immunosuppression 
2. Intravenous immunoglobulin 0.5 gm/kg/dose for four doses 
3. Cidofovir 0.5 mg/kg single dose44 
 It is a cytosine analogue that inhibits viral DNA polymerase. Cidofovir 
is highly concentrated in renal tissue and urine, so lower doses might be 
adequate to treat renal or bladder involvement. Even treatment of dialysis 
dependent renal failure due to adenovirus can recover following cidofovir 
therapy45. 
 Other drugs useful are ribavirin, ganciclovir, and vidarabine.  
POLYOMA VIRUS-ASSOCIATED NEPHROPATHY 
 Polyoma virus was first isolated from a kidney transplant recipient with 
a ureteric stricture. After kidney transplant, 10% to 60% of patients excrete the 
virus in their urine. The viruria in polyoma virus is asymptomatic or associated 
with only transient graft dysfunction. BK virus nephropathy has profound 
effect in allograft survival and quality of life. Roughly 30 to 60 % of patients 
with polyoma virus nephropathy develop graft failure. 
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 Primary infection with BK virus occurs during early childhood. The 
common mode of transmission is respiratory secretion. The seroprevalence in 
adults is more than 70%. BK virus latent infection is established in renal 
tubular epithelial cells. The virus may be in the episomal form or incorporated 
into the host cell genome. During latent infection few viral transcriptions occur, 
so it evades from host immunity during latency. BK virus remains latent in 
endothelial cells, connective tissue cells, renal tubular cells, blood leukocytes, 
ependymal cells of brain and astrocytes. Asymptomatic viruria occurs in 5% of 
healthy individuals. Viruria is common in mild immunodeficiency state like 
pregnancy, diabetes and elderly. The prevalence of viruria may increase with 
immune dysfunction to reach more than 60%. The prevalence rate of 
polyomavirus nephropathy varies from 1% to 10% in renal transplant 
recipients.  
Mode of spread 
a. The donor kidney itself 
b. The possibility of fecal/oral transmission recently has been raised by the 
demonstration of viral DNA in urban sewage 
c. Urine 
d. Nasopharyngeal aspirate obtained from infants with respiratory 
infections 
e. Sexual contact particularly for reactivation  
f. Transplacental route 
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Risk factors 
1. BK virus–seronegative recipients. 
2. BK virus–seropositive donors. 
3. Intense triple-drug immunosuppression with agents including 
calcineurin inhibitors particularly tacrolimus3 
4. Renal transplant 
5. HLA antigen mismatches 
6. Rejection and antirejection treatment  
7. Low number BK virus–specific interferon-8–producing T cells2 
Pathogenesis 
 Polyoma virus entry into host cells depends on caveola-mediated 
pathway. Factors contributing to nephropathy are defective surveillance by T 
cell, absence of viral specific humoral immunity and alloimmunization5.  
 It was found that patients with polyoma virus nephropathy had reduced 
number of BKV-specific IF-⅟-secreting lymphocytes. When the 
immunosuppression is reduced there is increase in the IF-⅟-secreting 
lymphocytes. After full resolution of infection there is 4 fold rise in IF-⅟ levels. 
 Viral genome contains epitopes within large T cell antigen, and VP1 
gene product, which are responsible for lymphocytes recognition. Site within 
viral T cell antigen particularly P53 binding region of large T cell antigen, 
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promoted CD8+ T cell response. In the same way two regions of viral capsid 
protein VP1 were recognized by cytotoxic T lymphocytes. It was observed that 
viral agnoprotein levels are increased after infection, which would contain 
epitopes for T cell stimulation. 
 The role of humoral immunity is suggested by the fact, that recipient of 
a kidney from a seropositive donor was more likely to develop polyoma 
viremia. Recipient seronegativity was a significant risk factor for polyoma 
viremia.  
 Polyoma virus nephropathy does not occur in liver and heart 
transplantation. There is more incidence of polyoma virus nephropathy when 
there is a higher degree of HLA mismatches. Polyoma virus nephropathy is 
specific to renal allograft recipient. It indicates subclinical alloactivation in 
graft may trigger nephropathy. 
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Type of immunosuppressive regimen  
 BK virus nephropathy is more common with the use of tacrolimus when 
compared to cyclosporine and mycophenolate mofetil when compared to 
azathioprine. Immunosuppressive agents containing tacrolimus-MMF 
combination is the most permissive regimen for BK virus reactivation. Lower 
incidence of BK virus nephropathy is also associated with steroid avoidance or 
early steroid withdrawal regimen. BK virus replication has also been associated 
with higher dose of MMF or tacrolimus. Improvement or stabilization of 
nephropathy occurs with dose reduction. 
Clinical features 
 Polyoma virus nephropathy occurs within the first post transplant year. 
Patients are usually asymptomatic and present with unexplained graft 
dysfunction.  
 Primary infection-hemorrhagic and non hemorrhagic cystitis, and 
tubulointerstitial nephritis. 
      Reactivation- hemorrhagic cystitis or hematuria, tubulointerstitial nephritis 
and occasionally they present with renal dysfunction secondary to ureteric 
stricture. Sometimes they present with severe systemic symptoms with multi 
organ failure. The cystitis that is common in polyoma virus is late onset and 
long duration hemorrhagic cystitis. Reactivation in other organ causes 
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meningoencephalitis, interstitial Pneumonitis, atypical retinitis, renal and 
urinary tract neoplasm57. 
Diagnosis  
 Renal biopsy is the gold standard for the diagnosis of polyoma virus-
associated nephropathy4. There is focal involvement; it is advisable to evaluate 
at least two cores of renal tissue59. The characteristic finding on light 
microscopy is the intranuclear basophilic viral inclusions in uroepithelial cells. 
 In early stages viral changes are present with little to no inflammation or 
tubular atrophy. In late stages viral cytopathic changes are associated with 
varying degrees of inflammation, tubular atrophy, and fibrosis. In latter stage 
cytopathic changes are less apparent, in the back ground of interstitial fibrosis, 
tubular atrophy and chronic inflammatory infiltrate. 
 Other morphologic features include glomerular crescents, transplant 
glomerulopathy, tubular micro calcification, and abundant plasma cell 
infiltration. 
 Simian virus 40 immunoperoxidase staining is useful in differentiating 
lesions mimicking acute cellular rejection with lymphocytic infiltration. 
Tubular basement membrane staining for C4d staining occurs in some and is 
associated with more severe disease. Higher proportion of CD20+ positive cells 
in the kidney biopsy well correlated with polyoma virus nephropathy. 
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Urine  
 Decoy cells originate from infected renal tubular cells altered by viral 
inclusion, are identified in polyoma virus nephropathy6. The characteristic 
feature of BK virus is large homogenous basophilic nuclear inclusions. Decoy 
cells may also be seen in JC virus and less commonly adenovirus infection. 
Decoy cell in urine has a sensitivity of 25% for BK viruria7. 
Urine VP1 mRNA indicates active viral infection. 
 Urine PCR has a sensitivity of 100% for BK viruria57. The interval from 
viruria to viremia is one to three months. The median time from viremia to BK 
virus nephropathy is 1 to 12 weeks.  
 Threshold for diagnosis of BK virus nephropathy is plasma viral load > 
10⁴ copies/ ml, higher viral load is correlated with more severe disease8. 
Nephritis can also occur with BK virus DNA <7000 copies/ml66.  
Treatment 
 The treatment of BK virus nephropathy is reduction of 
immunosuppression. The immune reconstitution controls infection after 4 to 12 
weeks. Patients who had polyoma virus infection, and inadvertently given pulse 
corticosteroids, or anti lymphocyte agent for presumed acute rejection have a 
rapid worsening of graft function.  
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The university of Maryland protocol involves three steps.  
Step1- Decrease the dose of MMF by 50% immediately after diagnosis. 
Step2- Reduce the trough level of tacrolimus at three months if decoy cells 
persist. 
Step 3- Withdraw MMF at 6 months if there is persistence of decoy cells. If 
there is no response, reduce the calcineurin inhibitor dose to maintain a target 
level between 3to5 ng/ml for tacrolimus and 50 to 100 ng/ml for cyclosporine. 
There is 10 to 15% chance of acute rejection with reduction of 
immunosuppression9.  
Anti viral therapy 
 Leflunomide-a pyrimidine analogue immunosuppressant, is also an 
immunomodulatory drug. It acts by inhibiting mitochondrial enzyme dihydro-
orotate dehydrogenase, which acts in the de novo synthesis of the pyrimidine 
ribonucleotide uridine monophosphate. Leflunomide primarily acts on 
activated and autoimmune lymphocytes by interfering with their cell cycle 
progression. The non-lymphoid cells are able to use salvage pathway to make 
their ribonucliotides, which make them less dependent on de novo synthesis. It 
has anti-inflammatory effect, in addition to antiproliferative activity.  
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  Leflunomide is metabolized to teriflunomide, after oral absorption, 
which is responsible for all of the drug's activity in vivo. This metabolite of 
teriflunomide has anti viral properties, in addition to immunosuppressive 
properties58. 
 Teriflunomide is metabolized in the liver by cytosolic and microsomal 
enzymes and further excreted in both urine and bile. After oral administration, 
peak plasma levels of teriflunomide occur between 6 and 12 hours after dosing. 
Teriflunomide has a long half-life of approximately 2 weeks.  
 A loading dose of 100 mg for 3 days is administered to reach steady-
state levels quickly. When loading dose is not given, the steady-state plasma 
concentrations would be achieved in two months of dosing. Teriflunomide can 
be found in human plasma at sufficient levels upto 2 years after termination of 
therapy. Teriflunomide is not dialysable. 
 Leflunomide should be started with the simultaneous discontinuation of 
antiproliferative agent and decreasing the dose of tacrolimus. With this 
treatment there is reduction in viral load.  
Contraindications  
 Pre-existing pregnancy or women of childbearing potential not using 
reliable contraceptive methods are an important contraindication. Women 
should not become pregnant before 2 years after termination of therapy as the 
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drug is slowly cleared. -Preexisting liver or renal disease -Moderate to severe 
diseases of the bone marrow or immune system -Severe bacterial, fungal or 
viral infections like active TB, pneumonia, AIDS or latent HIV  
Side effects 
 The most serious side effect is hepatitis, which can be fulminant, with 
severe liver necrosis, and liver cirrhosis. The incidence of severe liver damage 
is as high as 0.5%. The liver damage is typically seen within the first 6 months 
of therapy and it partially depends on concomitant administration of other 
hepatotoxic drugs. Risk factors for severe liver damage include history of 
alcohol abuse, acute heart failure, severe pulmonary disease or liver function 
disturbance.  
 Hematological side effecs are myelosuppression with leukopenia, 
anemia, and/or thrombocytopenia. Infectious side effect includes development 
of active tuberculosis, PCP,  pneumonia, and severe viral or mycobacterial 
infections, possibly leading to sepsis, death. Anemia or bleeding episodes may 
cause serious complications. 
  Interstitial lung disease present as progressive dyspnoea and typical X-
ray findings, which may or may not be reversible upon treatment. ILD may 
lead to permanent disability or death. To slow or reverse the severe side-
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effects, rapid removal of toxic metabolite is done by oral cholestyramine or 
activated charcoal. 
Cidofovir is an antiviral drug belonging to nucleoside analogue drug. When 
there is failure to respond to immunosuppressive dose reduction, cidofovir can 
be administered. 
Dose – The dose recommended for polyoma virus nephropathy is 10 to 20% of 
the dose needed in CMV infection (0.25 to 1.0 mg/kg). Side effect- cidofovir 
toxicity mainly involve the kidneys Proteinuria more than 2+ and renal failure 
occurs in upto 60% of patients receiving a maintenance dose of 5 mg/kg every 
fortnightly. Cidofovir nephrotoxicity is irreversible. Renal impairment, 
including cases of acute renal failure resulting in dialysis or contributing to 
death, can occur with as few as one or two doses of the drug. Prevention- 
Adequate hydration and concomitant administration of probenecid decreases 
the risk of renal toxicity associated with cidofovir. Proteinuria is an early 
indicator of cidofovir-associated nephrotoxicity. Before each dose of cidofovir 
administration, serum creatinine concentrations and urinalysis should be 
monitored. Patients who had previously received foscarnet are at increased risk 
of renal toxicity and should be monitored closely. Other effects are 
neutropenia, anaemia, thrombocytopenia, decreased intraocular pressure, 
nausea, vomiting, diarrhoea, abdominal pain, pancreatitis, fever, decreased 
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serum bicarbonate and fanconi’s syndrome, hepatitis, hepatic necrosis, 
dyspnoea and pneumonia. 
Fluoroquinolones have anti-BK properties through inhibition of DNA 
topoisomerase and polyomavirus associated large T-antigen helicase .In vitro 
analysis has shown that fluoroquinolones - nalidixic acid and oxolinic acid are 
capable of inhibiting BKV DNA replication. Other fluoroquinolones 
trovafloxacin, ciprofloxacin, levofloxacin, ofloxacin, and gatifloxacin also have 
the ability to inhibit viral DNA replication and T-antigen helicase activity of 
SV40. In permissive monkey cells, fluroquinolone has the ability to inhibit 
viral replication and block the cytopathic effect of SV40 virus.  
 The use of a 1-month course of fluoroquinolones immediately after the 
transplantation was associated with a significant reduction in the incidence of 
BK viremia. 
 Prophylaxis – with ciprofloxacin in hematopoietic stem cell transplant 
recipients, decrease the incidence of BK viruria and significantly reduces the 
rate of hemorrhagic cystitis.  
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RESULTS 
The total number of patients included in the study was 141  
58 (41%) patients who had at least one episode of urinary tract infection  
The number of male patients included in the study was110 
The mean age in male cohort was 33.70±8.77 years 
The number of female patients included in the study was 31  
The mean age in the female cohort was 30.18±10.54 years 
Recipient profile and urinary tract infection 
Recipient Urinary infection No urinary infection 
Male 41 69 
Female 17 14 
P-value 0.099 
Urinary tract infection occurred in 37 % of male patients and 54% of female 
patients. The incidence of urinary infection in female recipients was more when 
compared to male recipients, which did not reach statistical significance. 
The number of patients who received live related donor renal transplant was 
100 
The mean age of patients in this group was 30.35±9.42 years 
The number of patients who received deceased donor renal transplant was 41  
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The mean age of patients in this group was 36.46±8.77 years  
Donor profile and urinary tract infection 
Donor Urinary infection No urinary infection 
Live related donor 43 57 
Deceased donor 15 26 
P-value 0.57 
Incidence of urinary infection in live donor transplant recipients was 43% and 
in deceased donor recipients was 37%. There is no significant difference in the 
incidence of urinary tract infection with regard to donor status. 
 Profile of organisms in relation to time of post transplant- ( )-female 
Organism <1month 2-6months  >6months  
Candida 4 (1) 0 1 (1) 
Klebsiella 11 (5) 8 (1) 11 (2) 
E. coli 7 (1) 6 (1) 7 (6) 
CONS 2 1 1 
Enterococcus 1 1 1(1) 
Acinetobacter 1 1 (1) 1 
Proteus 0 1 0 
Pseudomonas 1 (1) 0 2 
Culture neg 1 2 0 
Within bracket- number of females, CONS- Coagulase negative 
staphylococcus, Culture neg- Culture negative 
The organism most commonly isolated was Klebsiella in 30 episodes of urinary 
tract infection, followed by E. coli in 20 episodes.  
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According to time of post transplant, in the 1st month Klebsiella urinary tract 
infection is more common in both males and females. In the 1 to 6months 
period post transplant and more than 6month post transplant also klebsiella 
urinary infection is more common in males. In females the common organism 
in the more than 6months post transplant is E. coli and in the 1 to 6 months post 
transplant there is equal occurrence of Klebsiella and E. coli urinary tract 
infection.  
Among the gram positive organisms coagulase negative staphylococcus was 
isolated in three patients, Staphylococcus aureus in one, and Enterococcus 
species in three patients. The gram positive organism as a cause of urinary tract 
infection occured in 1st month, 1 to 6 months and more than 6 months post -
transplant in male cohort with particularly Coagulase negative staphylococcus  
The other gram negative organisms isolated include Acinetobacter in two 
patients, Proteus in one and Pseudomonas in three patients. 
No organism could be identified in 3 patients with clinical features of urinary 
tract infection like pyuria, fever and tenderness over graft, which subsided with 
antibiotic treatment. Culture negative urinary tract infection occurred in 
3episodes, with one episode of pyelonephritis of the graft, in allograft biopsy 
done in the early post transplant period for evaluation of graft dysfunction at 
10th day post transplant. 
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Fungal urinary tract infection occurred in 5 patients, with 4 episodes occurring 
in less than 1 month post transplant. All the episodes of fungal urinary 
infections were due to Candida albicans. Three patients were treated with 
intravenous amphotericin for a total cumulative dose of 750mg.  
One patient with Candida urinary infection was treated with oral Fluconazole 
for 2 weeks. One patient had fungal urinary infection after 2 year post 
transplant with failed allograft due to hyper delayed graft function in the early 
period, severe steroid resistant rejection requiring lymphocyte depleting agent 
with recurrent bacterial urinary tract infection. 
Catheter days and urinary infection Catheterisation of bladder is a usual 
procedure in post renal transplant to favour healing of neo-cystourethrostomy. 
The relation between duration of catheterisation and the incidence of urinary 
tract infection is analysed 
Catheter days Urinary tract infection No urinary tract 
infection 
mean± S.D 9.69 ± 2.74 8 ± 1.79 
P-valve >1 
 
 
Mean number of catheter days with urinary tract infection was 9.69±2.74 days. 
The mean number of catheter days in those without urinary tract infection was 
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8±1.79 days. In subgroup analysis there is correlation of urinary infection with 
catheter days.  
Catheter days 
Urinary tract 
infection 
Without 
urinary tract 
infection 
Total number Percent 
< 7days 13 44 57 23% 
7-10 days 25 33 58 47% 
>10days 20 6 26 77% 
P-value 0.00016 
In patients with indwelling bladder catheterisation less than 7 days urinary 
infection occurred in 13 out of 57 patients. In patients with indwelling bladder 
catheterisation for 7 to 10 days, urinary tract infection occurred in 25 out of 58 
patients. In those with indwelling catheterisation for more than 10 days urinary 
tract infection occurred in 20 out of 26 (75%) patients. There is a statistically 
significant correlation between the incidence urinary tract infection and the 
duration of indwelling bladder catheterisation  
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Stenting and urinary tract infection 
50 patients out of 141 underwent prophylactic stenting in the study group. 
Mean number of days of stenting in those without urinary tract infection was 
47.45±13.58. The mean number of days in those with urinary tract infection 
was 43.30±6.42. There is no significant correlation of duration of stenting in 
those with and in those without urinary tract infection. P value 0.21 
Stenting and urinary tract infection 
Stenting Urinary tract infection No urinary tract 
infection 
Deceased donor 9 33 
Live donor 5 3 
 P-value 0.03 
In those patients who underwent prophylactic stenting 9 out of 42 patients in 
the deceased donor group had urinary tract infection. 
In the live donor group, those who underwent prophylactic stenting 5 out of 8 
recipients developed urinary tract infection.  
There is a significant correlation with more of live related renal recipient with 
prophylactic stenting developing urinary tract infection. 
 
Urinary infection and graft outcome  
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Serum creatinine in 
mg/dl 
Urinary tract infection Without urinary tract 
infection 
Mean 1.718 1.484 
Standard deviation 0.87 0.55 
P-value 0.037 
The mean serum Creatinine in those with urinary tract infection was 1.718 The 
mean serum Creatinine in those without urinary tract infection ws 1.484 There 
is a significant correlation of urinary tract infection with poor allograft outcome 
which is manifested as raised serum creatinine in those with urinary tract 
infection.  
Delayed graft function and urinary tract infection  
Graft function Urinary tract infection No urinary tract 
infection 
Early graft function 48 75 
Delayed graft function 10 8 
P-value0.2044                                                                                                                  
Early graft function is defined as postoperative urine output more than 7000ml 
and serum creatinine normalised in 3 to 7 days.  
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Delayed graft function is defined as the need for dialysis in the first week in 
the absence of Hyperkalemia and when urinary obstruction, vascular occlusion 
or hyper acute rejection are ruled out as a cause for slow graft function. In the 
first 6 hours post-operatively, there will be rise in serum creatinine or urine 
output less than 300ml in the absence of volume depletion and adequate dose 
of diuretics. Serum Creatinine fall less than 25% from baseline in the first 24 
hours and less than 10% fall from base line in 48 hours. When serum creatinine 
did not fall in the first 48 hours in the absence of rejection, delayed graft 
function is considered.  
Urinary tract infection occurred in 10 of 18 patients with early graft function. 
Urinary infection occurred in 48 of 123 patients with delayed graft function. 
Even though a trend towards more urinary tract infection in those with delayed 
graft function, than in those with early graft function, there is no statistical 
significance.  
Hepatitis C virus infection and UTI 
Hepatitis C virus Urinary tract infection No urinary tract 
infection 
HCV infection 18 10 
No HCV infection 40 73 
P-value 0.0091                                                          
Urinary tract infection occurred in 18 out of 28 patients with hepatitis C co-
infection. Urinary tract infection occurred in 40 out of 114 patients without 
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hepatitis C infection. There is a strong significant correlation with hepatitis C 
co-infection and urinary tract infection in the post transplant period. 
Diabetes mellitus and urinary tract infection 
Diabetic status Urinary tract infection No urinary tract 
infection 
Diabetes mellitus 18(1) 25(5) 
Non-diabetic 40 58 
P–value 1.00  
  Urinary tract infection occurred in 18 out of 43 patients with diabetes 
mellitus. Urinary tract infection occurred in 40 out of 98 patients in those 
without diabetes. Diabetes mellitus was noted in 43 out of 141 patients. Pre 
transplant diabetes mellitus was noted in 5 patients in those with urinary tract 
infection. New-onset diabetes post transplant was noted in 20 patients without 
urinary tract infection and 17 patients with urinary tract infection.  
There is no statistically significant correlation of the incidence urinary tract 
infection in those with diabetes mellitus and in those without urinary infection  
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Acute rejection episodes and urinary tract infection 
Rejection  Urinary tract infection No urinary tract 
infection 
Acute rejection/anti-
rejection therapy 
16 29(5) 
N o anti-rejection 
therapy 
42 54 
P-value 0.463 
Empirical antirejection therapy was administered in 5 patients, in those without 
urinary tract infection group. 
Urinary tract infection occurred in 16 out of 45 patients, who received anti-
rejection therapy. Urinary tract infection occurred in 42 out of 96 patients, who 
never received ART.  
There is no significant correlation with anti rejection therapy and the 
occurrence of urinary tract infection in renal transplant recipient.  
Cytomegalovirus infection and urinary tract infection 
Cytomegalovirus Urinary tract infection No urinary tract 
infection
CMV disease 7 8 
No CMV disease 51 75 
P-value 0.7828  
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Urinary tract infection occurred in 7 out of 15 patients who had 
cytomegaloviral disease. There is no correlation with cytomegalovirus disease 
and the occurrence of urinary tract infection in transplant recipient 
Structural abnormalities 
Structural 
lesions 
Age/Sex organism Time of 
occurrence 
Number of 
episodes 
comorbidities 
Ureteric 
stricture 
26M Klebsiella 
oxytoca 
11month 1 HCV infection/ 
ART 
Ureteric 
stricture with 
VUR 
21M Klebsiella 
oxytoca 
4th day, 10th 
month, 12th 
month 
3 Anti-rejection 
therapy (ART) 
Meatal stenosis 20M Culture 
negative 
3rd month 1 HCV infection 
PUJ 
obstruction 
45M E. coli 1year 5month 1 NODAT 
Scar in the 
kidney 
34F E. coli 6year 1 HCV infection 
Neurogenic 
bladder 
35 M Klebsiella 
oxytoca 
2month 
onwards 
6 CMV infection 
Horse shoe 
kidney 
22M No  0 Anti-rejection 
VUR 30M No  0  
 
Pretransplant structural abnormalities were identified in 7patients and 
neurogenic bladder dysfunction due to spinal injury was present in one patient.  
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Three patients had bladder outlet obstruction, one had meatal stenosis and other 
two patients had ureteric stricture.  
Isolated vesicoureteric reflux, horse shoe kidney, scar in the allograft and pelvi-
ureteric junction obstruction -each present in one patient.  
Three patients had urinary tract infection in the 1 to 6 month period. Three 
patients present with urinary tract infection in the late post transplant period. 
Acute rejection occurred in 3 out of 7 patients with structural abnormalities, 
with two patients with stricture urethra having late rejection. 
Among them, one patient had transplant ureteric stricture in the 11th post 
transplant month. He received live related transplant with father as donor, on 
triple immunosuppression with tacrolimus, mycophenolate mofetil and 
Prednisolone. He had chicken pox in the 8th post transplant month. He had 
gradual worsening renal failure, with gross hydroureteronephrosis of transplant 
kidney, requiring dialysis. He initially underwent percutaneous nephrostomy, 
followed by pyeloureteroplasty. He developed klebsiella urinary tract infection 
after 3 weeks of procedure. 
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Graft pyelonephritis  
No Age/sex NODAT HCV Rejection  Outcome  Co-morbidity 
1  56F Yes No No 3.1-1.0mg Stenting45days 
2  23M No No No 3.5-2.4mg Stenting56days 
3  27M No No Yes steroid 
2.5gm 
Dialysis 
dependent 
 
4  26M Yes Yes No 2.5-1.6mg Transplant ureteric 
stricture.stent21days
 
Four patients presented with low grade fever and graft dysfunction. All of them 
underwent allograft biopsy for graft dysfunction. All patients had no urinary 
symptoms in the form of dysuria, frequency and pain or tenderness over the 
graft. One patient had transplant ureteric stricture, for which he underwent 
pyeloureteroplasty to native ureter with double J stenting. The stent was 
removed after three weeks after that he presented with graft dysfunction and 
diabetic ketoacidosis. One patient with pyelonephritis in the allograft biopsy 
received steroids 2.5gms in the previous week for acute cellular rejection, 
masking the symptoms of UTI. Diabetes was present in two of the patients. 
Stenting was done in 3 out of four patients. All of those with stenting 
developed urinary tract infection immediately after stent removal. Two patients 
had recovery of renal function following treatment of urinary tract infection. 
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One patient had partial recovery of renal function. One patient gradually 
progressed to end stage renal disease over a period of 5months. 
Renal abscess  
 No  Age /sex HepatitisC Sr creatinine organism duration Outcome 
1  37/M Yes 1.8mg pseudomonas 1yr 10 
month 
Per-cutaneous 
drainage 
2  24/F CMV 
twice 
1.6mg E. coli 2yr 
4month 
Per-cutaneous 
drainage 
 
Renal abscess occurred on the late post transplant period, more than 18 month 
post transplant. The serum creatinine at the time of abscess formation was 
1.8mg and 1.6mg respectively in the two patients.  
Recurrent urinary tract infection 
Recurrent UTI is defined as occurrence of more three episodes per year. Out of 
58 patients with urinary tract infection, six patients had recurrent episodes of 
infection. 
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S.No Age/sex No of 
episodes 
donor NODAT HCV Anti-
rejection
DGF Stent 
duration 
0ther co-
morbidities
1 47M 4 E. coli live Yes Yes Yes/late No No FSGS 
recurrence 
2 24M 7 kleb live Yes Yes No No No Hepatitis 
3 43M 5 kleb cadaver Yes No No Yes 42days Expanded 
donor 
4 41m 3 kleb cadaver Yes Yes Yes/late Yes 42days Hepatitis 
5 35M 6 kleb live No No No No 42days CMV/ 
neurogenic 
bladder 
6 22M 3 kleb cadaver No No No No 42days IgA 
recurrence 
 
Kleb-klebsiella, cadaver- deceased, FSGS-focal segmental glomerulosclerosis, 
IgA-immunoglobulin A, CMV-cytomegalovirus, NODAT-new onset diabetes 
after transplant 
The organism most commonly isolated in those with recurrent UTI was 
klebsiella oxytoca, and in one patient E. coli.  
One out of 6 received induction therapy in the form of 2 doses of basiliximab. 
All the patients were on triple immunosuppression, with three on tacrolimus, 
MMF and steroid, and other three on cyclosporine, Azathioprine and steroid.  
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NODAT was noted in 4 out of 6 patients with recurrent urinary tract infection. 
HCV infection occurred in 3 out of 6 patients with recurrent urinary tract 
infection; two of them had active hepatitis with worsening liver function also. 
Rejection episodes occurred in 2 out of 6 patients, with both patient developing 
late rejection after multiple episodes of urinary tract infection. 
Recurrence of disease (FSGS/IgA nephropathy) occurred in 2 out of 6 patients, 
with proteinuria occurring from third post transplant month.  
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DISCUSSION 
 Infection is a common complication in the renal transplant recipient. In 
the initial months of post transplant period bacterial infection is more common, 
with urinary tract infection occurring as a common infection among bacterial 
infections. 
 According to Hussain et al the incidence of urinary tract infection was 
46%69. The incidence of urinary infection in our cohort was 41%. The reported 
frequency varies in various studies ranging from 18% to 79%.  
 According to Roberto Rivera-Sanchez et al et al, E. coli was the most 
common organism 31%, followed by candida albicans 21% and enterococcus 
species 10%19. In our study klebsiella species is the most common organism 
isolated followed by E.coli. Among gram positive organism coagulase negative 
staphylococcus urinary tract infection is more common. 
  According to Lyrova et al there is no significant difference in graft 
function and allograft survival in those who have developed urinary tract 
infection during a follow-up of 5 years87. According to Pelle et al there is a 
poor long term outcome in those with acute graft pyelonephritis, documented 
by a lower creatinine clearance by 50% in those with post transplant UTI, when 
compared to those without urinary tract infection over 4 years follow up24.  
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 In our cohort also there is a significantly worse graft outcome in the 
form of raised creatinine in those with urinary infection when compared to 
those who never had urinary tract infection.  
 According to Kamath et al there is a correlation with pre transplant 
glomerular disease and urinary infection1. According to the author the pre 
transplant immunosuppression, by increasing the net immunosuppression post 
transplant predisposes to urinary infection. In our cohort there is increased 
incidence of urinary infection in those with proteinuria due to recurrent 
glomerular disease with two patients presenting as recurrent urinary tract 
infection, even though they received no immunosuppression during the pre 
transplant period.  
 According to Magali Gril et al there is more incidence of graft 
pyelonephritis in female recipient86. In our study also there is increased 
incidence of urinary tract infection in female recipient, which did not reach 
statistical significance. The increased incidence of urinary infection in female 
may be due to anatomic factors like shorter female urethra and proximity of the 
vagina and urethra to the anal canal favouring colonization49.  
  There is no correlation between diabetes, cytomegalovirus infection and 
rejection episodes with the increased incidence of urinary tract infection as 
shown in various study17.  
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 The incidence of urinary tract infection is more common in those with 
hepatitis C co-infection. Hepatitis C virus is an immunomodulating virus like 
cytomegalovirus and predispose to more risk of infections.  
  According to David Roth et al the risk of infection is considered as a 
function of time line, initial 6months and more than 6 months80. In the initial 
6months the morbidity and mortality due to all infections in the post transplant 
patient with HCV infection is increased by a factor of 2.51.  
 The infection risk is not increased in the late post transplant period. But, 
the risk for cardiovascular mortality is decreased significantly in post 
transplants irrespective of the time since transplantation.  
 When, the mortality due to infection alone is considered, it is increased 
by a factor of 26 fold, in post transplant when compared to pre transplant. In 
our study, in univariate analysis there is significantly increased risk of urinary 
tract infection in the post transplant, with hepatitis C co-infection.  
  Three patients with HCV co-infection post transplant presented with 
recurrent urinary infection72. Two patients developed jaundice with active 
hepatitis after repeated urinary tract infection, associated with worsening 
allograft function and succumbed to the illness. Among them one was 
asymptomatic for HCV pretransplant, with hepatitis C antibody negative and 
mild elevation of liver enzymes, and nucleic acid test was not done pre-
transplant for him74. He was on triple immunosuppression including 
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Azathioprine, which would have worsened his hepatitis. The pre- transplant 
diagnosis of hepatitis C virus status using nucleic acid based testing22 might 
have been useful in choosing the non Azathioprine containing 
immunosuppression and optimization of immunosuppression, so that over 
immunosuppression can be avoided, which may be helpful in reducing 
infection related death including urinary tract infection and progression of liver 
disease21. 
  According to Tanweer Iqbql study there is a significant correlation 
between the number of catheter days and urinary tract infection, with more 
urinary tract infection whenever the catheter was retained for prolonged 
periods66. In our study also there is a strong linear correlation with the number 
of days of catheterisation and occurrence of urinary tract infection. In patients, 
in whom the catheter was retained for less than 7days, 23% developed urinary 
tract infection. In those patients in whom the catheter was retained for 7 to 10 
days, 47% developed urinary tract infection. When catheter was retained for 
more than 10 days, about 77% of patients developed urinary tract infection in 
the post transplant period. 
  Urinary catheterisation was done by the urologist in the immediate post-
transplant period and continuous bladder drainage was being maintained to 
avoid the early urological complication like urine leak. Whenever the drain 
volume was more than 30 ml operating surgeon in doubt of urological 
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complication, retain the bladder catheter for some more days. With every 
additional day of catheterisation, there is progressive increase in the percentage 
of patients developing colonization of the urinary tract, which commonly arise 
trough the peri-urethral route20.  
 With longer duration of catheterisation there is every chance of biofilm 
formation with the organism secreted substances and host factors, forming a 
protective barrier to the organism from the host immunological mechanism and 
administered antimicrobial substances, and multiple organisms in the colony of 
biofilm exchange genetic material between organisms including multidrug 
resistant plasmid. 
 The organism causing urinary tract infection in those with indwelling 
catheterisation frequently originate from the hospital environment, and due to 
biofilm formation have resistant to multiple antimicrobials20.  
 The surgeon should balance the risk of urological complication from 
early catheter removal which compromise the neo-ureterocystostomy and the 
risk of urinary catheterisation from retaining the catheter for a long period.  
  The anastomosis done in the renal transplant surgery between donor 
ureter and the recipient bladder is different from the other urological neo-
ureterocystostomy29.  
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  In routine urological procedure the diseased ureter is anastomosed to the 
diseased bladder making the anastomosis at risk of compromise when it is not 
supported by continuous bladder drainage30. 
 In the renal transplant surgery the anastomosis made between the 
healthy donor ureter and usually healthy recipient ureter making the risk of 
anastomosis complication less likely, so that early removal of catheter can 
reduce the incidence of catheter associated urinary tract infection in the 
profoundly immunosuppressed recipient in the early post transplant period.  
  In the same study the author compares the incidence of urinary tract 
infection in those with stenting and those without stenting. There is no 
increased incidence of urinary tract infection in in those with stenting when 
compared to those without stenting26. 
  In our study about 50 patients underwent prophylactic stenting. There is 
no significant difference in the duration of stent placement between those with 
urinary tract infection, with those without urinary tract infection. Most of our 
patient develops urinary tract infection within a week of stent placement, even 
though some may develop infection during stent insitu.  
  Stenting is the procedure done to avoid early urological complication in 
the post transplant patient. Stenting decrease the incidence of urine leak, 
ureteric stricture and kinking of the ureter which are the complication arising 
from neo ureterocystostomy. 
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  By creating tension free water tight ureterocystostomy anastomosis and 
preserving the vascular supply of the ureter by preserving the golden triangle 
and by avoiding any dissection, the early urological complications can largely 
be avoided.  
  Stenting predisposes not only to urinary tract infection and also to the 
formation of biofilm on the surface similar to that occurring in bladder 
catheterisation, predisposing formation of multi drug resistant organism. There 
is also increased incidence of late urinary stricture in those with prophylactic 
stenting.  
  In our study stent was kept for an average more than 6weeks. And there 
is also more urinary tract infection in live-related transplant when compared to 
deceased donor transplant with urinary stenting27. This may be due to the fact, 
in deceased donor transplant routine prophylactic stenting is being followed, 
since there is prolonged ischemic time and there is every chance for no urine 
output after clamp release, so ensuring water tight anastomosis may not be 
possible. 
  In live donor transplant, the indication for stenting may be abnormal 
bladder27, which may be risk factor for urinary tract infection by itself, and our 
study population with stenting in live related transplant is too small to make 
any comment regarding increased urinary infection in those with stenting. 
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  If at all stenting is done for avoiding early urological complication, it 
should be removed as early as possible preferably with in 3 to 4 weeks, to 
decrease the incidence of urinary tract infection. As most of the infections in 
the stented patients occur immediately after removal of stent, there should be 
close surveillance for urinary tract infection in the early stent removal period, 
so that any infection can be brought under control early.  
 Renal abscess occurred in two patients in our study. The occurrence of 
infection is due to infection with immunomodulatory viruses predisposing to 
bacterial infections.  
 Patients may have few signs or symptoms of infection because of their 
immunosuppressed state. They may present with fever of unknown origin, 
pain, or symptoms related to the pressure of the abscess on the transplanted 
system. Peri-transplant abscesses usually develop within the first few weeks 
after transplantation. Abscess is usually caused by infection of peri-nephric 
collection or from complication of pyelonephritis. Abscesses may be treated 
with either ultra sound or CT-guided percutaneous drainage. Both intrarenal 
and extrarenal abscesses usually respond to percutaneous drainage and 
systemic antibiotics. In our patient the late occurrence of renal abscess 
complicating urinary tract infection is due to both of them having 
immunomodulatory viral infection, hepatitis C virus in one and recurrent 
cytomegalovirus in the other patient. Both patient underwent imaging guided 
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percutaneous aspiration, but had progressive worsening of the disease and 
succumbed to the illness88.  
 One patient presented with E. coli urinary tract infection with renal 
abscess 2year 4months post transplant. She was on triple immunosuppression 
based on cyclosporine, Azathioprine and steroid. She had three episodes of 
cytomegalovirus infection. The other presented with pseudomonas urinary tract 
infection with psoas abscess 18 months post transplant. He was diagnosed to 
have HCV co-infection after transplant, and he was also on triple 
immunosuppression based on cyclosporine, Azathioprine and steroid. 
Cytomegalovirus infection causes immunomodulation by three mechanisms 
1.Cytomegalovirus reduces cell surface expression of major histocompatibility 
complex class I antigen on the surface of cells impairing T-cell recoganization. 
2. Cytomegalovirus produces IL-10 which inhibits proliferation and cytokine 
production by mononuclear cells. It also inhibits maturation and induces 
apoptosis of dentritic cells. 3. Cytomegalovirus causes suppression of antigen 
specific cytotoxic T lymphocyte function and cause a decrease in CD4+ cell 
function leading to global impairment of cell-mediated immunity. 
 In this manner it predisposes the patient to bacterial, fungal and parasitic 
infection. The indirect effects of cytomegalovirus are rejection and 
predisposition to opportunistic infection, causing decreased patient and graft 
survival17. 
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 Polyoma virus nephropathy presenting as transplant ureteric stricture 
occurred in one patient, and he was on triple immunosuppression with 
tacrolimus, mycophenolate mofetil and steroid. He presented with ureteric 
stricture in the 8th post transplant month which is the usual presenting time of 
polyomavirus nephropathy reactivation. Polyoma virus usually manifests in the 
6 to 18 month post transplant. Prosser et al used enzyme-linked immunosorbent 
spot assay to measure the cellular immunity in those with polyomavirus 
infection by analysing interferon gamma levels85. He demonstrated a fourfold 
rise in titre of interferon gamma levels with resolution of infection. This shows 
that the impact of intact cell-mediated immunity in the prevention of 
polyomavirus reactivation and why it occurs more commonly in those on 
potent immunosuppression tacrolimus when compared to cyclosporine. 
According to Aoron Dall et al polyoma virus infection are usually 
asymptomatic and polyoma viral infection occasionally present as stricture of 
transplant ureter84.  
 Awadalla et al showed, an increased HLA mismatches with occurrence 
of nephropathy, implying allo-immunisation as a potentiating factor for 
polyoma virus infection reactivation83. BK virus reactivation is rarely seen in 
those who have undergone non renal solid organ transplantation. The patient 
will usually be on triple drug including tacrolimus. The disease should be 
managed with reduction in antiproliferative drug, or temporary withdrawal of 
the drug, which result in gradual reduction in viral load over 12 weeks. Some 
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may also need the reduction of calcineurin inhibitor to achieve maximum 
therapeutic response. Acute rejection can occur in about 10% of the patient 
during tapering of immunosuppression, which should be actively sought during 
reduction of immunosuppression.  
  In our cohort there is no case of documented adenovirus infection. One 
patient presented with hematuria and graft dysfunction. He underwent renal 
biopsy in the 30th post transplant day diagnosed as acute cellular rejection, and 
he was treated with anti rejection therapy. He had very high cyclosporine level, 
and developed fever and expired in the 2nd month post transplant. He might 
have suffered from adenovirus infection, since we have not tested him for 
adenovirus by PCR.  
 Adenovirus usually present in the early post transplant period with short 
history of hematuria, fever and biopsy showing interstitial mononuclear 
infiltrates81. The early recognition of this infection is needed, since it respond 
to low dose of single dose cidofovir with rapid recovery of renal function, even 
in those with dialysis requiring renal failure82. 
  Another patient in our cohort presented with hemorrhagic cystitis in the 
second post transplant month. He developed cytomegalovirus and klebsiella 
urinary tract infection in the 4th month post transplant. This shows that 
cytomegalovirus can also present as hemorrhagic cystitis.  
 
76 
 
 
 
  When patient presents with hematuria, they should be screened for 
adenovirus, cytomegalovirus and polyoma virus according to the time period in 
the post transplant setting.  
  
 
 
 
 
 
CONCLUSIONS 
1. Urinary tract infection is a common infection in renal transplant recipients. 
2. Klebsiella species is the commonest organism causing urinary tract infection 
in this study. 
3. There is no correlation with cytomegalovirus disease, pre existing diabetes, 
NODAT (New Onset Diabetes After Transplantation) and anti rejection 
therapy on the occurrence of urinary tract infection.  
4. The incidence of urinary tract infection is increased in those with hepatitis C 
virus coinfection.  
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5. Urinary infection is increased as a function of number of days of indwelling 
urethral catheterization post transplant, with more incidence of urinary tract 
infection with increased number of catheter days. 
6. The incidence of urinary tract infection is not increased in those with 
prophylactic stenting. 
7. Urinary tract infection in the renal transplant recipients is associated with 
poor long term graft function  
  
   
 
78 
 
 
 
 
 
 
 
    BIBLIOGRAPY 
1.Kamath NS, John GT, Neelakantan N, Kirubakaran MG, Jacob CK.: Acute graft 
pyelonephritis following renal transplantation. Transpl Infect Dis8: 140–147, 2006. 
2. Hirsch H. H., Brennan D. C., Drachenberg C. B., et al. Polyomavirus-associated 
nephropathy in renal transplantation: interdisciplinary analyses and recommendations. 
Transplantation. 2005;79((10)):1277–1286. 
3. Cosio F. G., Amer H., Grande J. J. P., Larson T. S., Stegall M. D., Griffin M. D. 
Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of 
efficacy by protocol biopsies. Transplantation. 2007;83((4)):411–416. 
4. Drachenberg C. B., Papadimitriou J. C., Hirsch H. H., et al. Histological patterns of 
polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant. 
2004;4((12)):2082–2092. 
5. Bohl D. L., Brennan D. C. BK virus nephropathy and kidney transplantation. Clin J Am 
Soc Nephrol. 2007;2((suppl 1)):S36–S46. 
6. DeMay R. M. The Art and Science of Cytopathology. Vol 1. Vol. 75. American Society 
Clinical Pathology; Chicago, IL: 1996. pp. 2160–2161. 
7. Viscount H. B., Eid A. J., Espy M. J., et al. Polyomavirus polymerase chain reaction as a 
surrogate marker of polyomavirus-associated nephropathy. Transplantation. 
2007;84((3)):340–345. 
8. Hirsch H. H., Knowles W., Dickenmann M., et al. Prospective study of polyomavirus type 
BK replication and nephropathy in renal transplant recipients. New Engl J Med. 
2002;347((7)):488–496. 
9. Wali R. K., Drachenberg C., Hirsch H. Intensive versus routine care screening for polyoma 
viral reactivation (cluster randomization) and a road map for stepwise modification of 
immunosuppression therapy (IT) Am J Transplant. 2008;8((suppl 2)):283. 
10 Tolkoff-Rubin NE, Cosimi AB, Russel PS, Rubin RH. A controlled study of trimethoprim-
sulfamethaxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev 
Infect Dis 1982;4(2):614-8.  
11. Alepoulos E, Memmos D, Sakellariou G, Paschalidou E, Kyrou A, Papadimitriou M. 
Urinary tract infections after renal transplantation. Drugs Exp Clin Res 1985;11(2):101-5.  
12. Abbot KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after 
renal transplantation in the Unites States. Transplant Infect Dis 2001;3(4):203-11.  
13 Pappas PG, Rex JH, Sobel JD, et al. Guidelines for the treatment of Candidiasis: Infectious 
Diseases Society of America. Clin Infect Dis 2004;38(2):161-89.  
14. Scott LJ, Simpson D. Voriconazole: A review of its use in the management of invasive 
 
79 
 
 
 
fungal infections. Drugs 2007;67(2):269-98.  
.15.Tolkoff-Rubin N & Rubin R. Urinary tract infection in the immunocompromised host. 
Lessons from kidney transplantation and the AIDS epidemia. Infect Dis Clin North Am 
1997; 11: 707–717. | 
16. Takai K, Tollemar J & Wilczek H et al. Urinary tract infections following renal 
transplantation. Clin Transplant 1998; 12: 19–23.  
17. Reinke P, Prosch S & Kern F et al. Mechanism of human cytomegalovirus (HCMV) (re) 
activation and its impact on organ transplant patients. Transpl Infect Dis 1999; 1: 157–164. 
18. Mathew T, Kincaid-Smith P & Vikraman P. Risks of vesicoureteric reflux in the 
transplanted kidney. N Engl J Med 1977; 8: 414–418. 
19. Karkkainen U, Ikaheimo R & Katila M et al. Low virulence of Escherichia coli strains 
causing urinary tract infection in renal disease patients. Eur J Clin Microbiol Infect Dis 
2000; 19: 254–259.  
20. Rabkin D, Stifelman M & Birkhoff J et al. Early catheter removal decreases incidence of 
urinary tract infections in renal transplants recipients. Transplant Proc 1998; 30: 4314–
4316. 
21.Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durant D, Izopet J.: Natural 
history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 
5: 1704–1712, 2005. 
22.Hanuka N, Sikuler E, Tovbin D, Mostoslavsky M, Hausman M, Orgel M, Years A, 
Shemer-Avni Y.: Hepatitis C virus infection in renal failure patients in the absence of anti-
hepatitis C virus antibodies. J Viral Hepat 9: 141–145, 2002.   
 23.VanBurkirk A, Burlingham W & Jankowska-Gan E et al. Human allograft acceptance is 
associated with immune regulation. J Clin Invest 2000; 106: 145–155. 
24.Pelle G, Vimont S, Levy PP. et al. Acute pyelonephritis represents a risk factor impairing   
long-term kidney graft function. Am J Transplant. 2007;7:899–907.  
25.Tavakoli A, Surange RS, Pearson RC, Parrott NR, Augustine T, Riad HN. Impact of stents 
on urological complications and health care expenditure in renal transplant recipients: results 
of a prospective, randomized clinical trial. J Urol. 2007;177:2260–2264.  
26.Hetet JF, Rigaud J, Karam G. Should double J catheter be systematically considered in 
renal transplantation? Ann Urol (Paris) 2006;40:241–246.  
27.Osman Y, li-El-Dein B, Shokeir AA, Kamal M, El-Din AB. Routine insertion of ureteral 
stent in live-donor renal transplantation: is it worthwhile? Urology. 2005;65:867–871.  
28. Goldfarb DA. Stented versus nonstented extravesical ureteroneocystostomy in renal 
transplantation: a meta-analysis. J Urol. 2005;173:889. doi: 10.1097/00005392-200503000-
00075. 
29.Mangus RS, Haag BW, Carter CB. Stented Lich-Gregoir ureteroneocystostomy: case 
series report and cost-effectiveness analysis. Transplant Proc. 2004;36:2959–2961. doi: 
10.1016/j.transproceed.2004.10.061. 
 
80 
 
 
 
30.Wilson CH, Bhatti AA, Rix DA, Manas DM. Routine intraoperative stenting for renal 
transplant recipients. Transplantation. 2005;80:877–882. 
10.1097/01.tp.0000181197.21706. 
31.Praz V, Leisinger HJ, Pascual M, Jichlinski P. Urological complications in renal 
transplantation from cadaveric donor grafts: a retrospective analysis of 20 years. Urol Int. 
2005;75:144–149. 
32. Minnee RC, Surachno S, Kox C, ten Berge IJ, Aronson DC, Idu MM. Is a selective 
splinted ureterocystostomy protocol feasible in renal transplantation. An analysis of 475 
renal transplantations? Transpl Int. 2006;19:558–62. 
33. Blanchet P, Hammoudi Y, Eschwege P, Droupy S, Bensadoun H, Hiesse C, et al. 
Urinary complications after kidney transplantation can be reduced. Transplant Proc. 
2000;32:2769. 
34. Crowe A, Cairns HS, Wood S, Rudge CJ, Woodhouse CR, Neild GH. Renal 
transplantation following renal failure due to urological disorders. Nephrol Dial 
Transplant. 1998;13:2065–9. 
.35. Sansalone CV, Malone G, Aseni P, Mangoni I, Soldano S, Minetti E, et al. 
Advantages of short time ureteric stenting for the prevention of urological complications 
in kidney transplantation: an 18-year experience. Transplant Proc. 2005;37:2511–5. 
36. Hayes JM, Streem SB, Graneto D, Hodge EE, Steinmuller DR, Novick AC. Renal 
transplant calculi. A re-evaluation of risks and management. Transplantation. 
1989;47:949–52. 
37. Challacombe B, Dasgupta P, Tiptaft R, Glass J, Koffman G, Goldsmith D, et al. 
Multimodal management of urolithiasis in renal transplantation. BJU Int. 2005;96:385–9. 
38. Ranganathan M, Akbar M, Ilham MA, Chavez R, Kumar N, Asderakis A. Infective 
complications associated with ureteral stents in renal transplant recipients. Transplant 
proc. 2009;41:162–4. 
39. Thomas A, Dropulic LK, Rahman MH, Geetha D. Ureteral stents: A novel risk factor for 
polyomavirus nephropathy. Transplantation. 2007;84:433–6. 
40 Gallego VE, Ortega CA, Llamas FF, Masiá MJ, Martínez FG, López RE, et al. Short cold 
ischemia time optimizes transplant results for kidneys from expanded criteria donors. 
Nefrologia. 2009;29:456–63. 
41 Hoffman JA Adenoviral disease in pediatric solid organ transplant recipients.  
         Pediatr Transplant 2006;10:17-25. 
42.Farrugia E, Schwab TR Management and prevention of cytomegalovirus infection                           
after renal transplantation. Mayo Clin Proc 1992;67:879-890. 
43.Ljungman P, Ribaud P, Eyrich M, et alCidofovir for adenovirus infections after allogeneic 
hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of 
the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 
2003;31:481-486. 
44.Cundy KC Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir 
and adefovir. Clin Pharmacokinet 1999;36:127-143. 
 
81 
 
 
 
45.Naesens L, Lenaerts L, Andrei G, et al 
.Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. 
Antimicrob Agents Chemother 2005;49:1010-1016. 
46.Ranganathan M, Akbar M, Ilham MA, Chavez R, Kumar N, Asderakis A. Infective 
complications associated with ureteral stents in renal transplant recipients. Transplant 
Proc. 2009 Jan-Feb;41(1):162-4. 
 47.Valera B, Gentil MA, Cabello V, Fijo J, Cordero E, Cisneros JM. Epidemiology of 
urinary infections in renal transplant recipients. Transplant Proc 2006;38(8): 2414-5.  
3
.
 
48.Khosroshahi HT, Mogaddam AN, Shoja MM. Efficacy of high-dose trimethoprim-
sulfamethoxazol prophylaxis on early urinary tract infection after renal transplantation. 
Transplant Proc 2006;38(7): 2062-4. 
49. Memikoğlu KO, Keven K, Sengül S, Soypaçaci Z, Ertürk S, Erbay B.  
Urinary tract infections following renal transplantation: a single-center experience.  
Transplant Proc. 2007 Dec;39(10):3131-4.. 
50.Nampoory MR, Johny KV, Costandy JN, Nair MP, Said T, Homoud H, Al-Muzairai 
I, Samhan M, Al-Moussawi M. Infection related renal impairment: a major cause of 
acute allograft dysfunction. Exp Clin Transplant. 2003;1:60–64. 
51.Alangaden G. Urinary tract infections in renal transplant recipients. Curr Infect Dis 
Rep. 2007;9:475–479. 
52.Colombo AL, Guimãraes T. Candiduria: a clinical and therapeutic approach. Rev Soc 
Bras Med Trop. 2007;40:332–337. 
53.Kumar MSA, Cridge P, Molavi A, Stephan R, Abouna GM. Infectious complications 
in the first 100 days after renal transplantation. Transplant Proc. 1995;27(5):2705–2706. 
54.Midtvedt K, Hartman A, Midtvedt T, Brekke IB. Routine perioperative antibiotic 
prophylaxis in renal transplantation. Nephrol Dial Transplant. 1998;13:1637–1641. doi: 
10.1093/ndt/13.7.1637. 
55.de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin 
Pract Nephrol. 2008;4:252–64.[PubMed] 
56. Senger SS, Arslan H, Azap OK, Timurkaynak F, Cağir U, Haberal M. Urinary tract 
infections in renal transplant recipients. Transplant Proc. 2007;39:1016–7. 
57.Pang XL, Doucette K, LeBlanc B, Cockfield SM, Preiksaitis JK. Monitoring of 
polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a 
quantitative real-time PCR assay: One-year prospective study. J Clin Microbiol. 
2007;45:3568–73. schitelli M, Bellizzi A, Anzivino E, Fioriti D, Boldorini R, Miglio U, et al. 
Complications post renal transplantation: Literature focus on BK virus nephropathy and 
diagnostic tools actually available. Virol J. 2008;5:38.[PMC free article][PubMed] 
59. Drachenberg CB, Papadimitriou JC, Hirsch HH, Wali R, Crowder C, Nogueira J, et al. 
Histological patterns of polyomavirus nephropathy: Correlation with graft outcome and viral 
 
82 
 
 
 
load. Am J Transplant. 2004;4:2082–92.[ 
60.Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, et al. 
Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses 
and recommendations. Transplantation. 2005;79:1277–86.[ 
61. Sqalli TH, Laboudi A, Arrayhani M, Benamer L, Amar Y, Ouzeddoun N. Urinary 
tract infection in renal allograft recipients from living related donors. Saudi J 
Kidney Dis Transplant 2008; 19: 551-53 
62.de Souza RM, Olsburgh J.: Urinary tract infection in the renal transplant patient. Nat Clin 
Pract Nephrol 4: 252–264, 2008.  
63.Johnson JR, Kuskowski MA, Gajewski A, Soto S, Horcajada JP, Jimenez de Anta MT, 
Vila J.: Extended virulence genotypes and phylogenetic background of Escherichia coli 
isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis 191: 46–50, 
2005.  
64. Garinis G, Spanakis N, Theodorou V, Manolis E, Karameris A, Valis D.: Comparison of 
the enzyme-linked immunosorbant assay III, recombinant immunoblot third generation assay, 
and polymerase chain reaction method in the detection of hepatitis C virus infection in 
haemodialysis patients. J Clin Lab Anal 13: 122–125, 1999.  
65.Johnson JR.: Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol 
Rev 4: 80–128, 1991. 
66. Tanweer Iqbal, Rubina Naqvi, Syed Fazal AkhterP: Frequency of urinary tract infection 
in renal transplantrecipients and effect on graft function.Department of Nephrology, Sindh 
Institute of Urology and Transplantation Karachi, Pakistan. 
67.Tolkoff-Rubin NE, Cosimi AB, Russell PS, Rubin RH.: A controlled study of 
trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant 
recipients. Rev Infect Dis4: 614–618, 1982. [PubMed] 
68.Fox BC, Sollinger HW, Belzer FO, Maki DG.: A prospective, randomized, double-blind 
study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: 
Clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and 
the cost-benefit of prophylaxis. Am J Med 89: 255–274 1990.  
69. Hussain Z, Rizvi SAH, Naqvi A, Zafar N, Ahmed E, Sultan S. Risk factors and 
adverse effects of urinary tract infections in live related allograft recipients. Am J 
Tran 2003; 507 Abs. 1385 poster board session: p141-111. 
70.Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM.: Relationship between hepatitis C and 
chronic kidney disease: Results from the Third National Health and Nutrition Examination 
Survey. J Am Soc Nephrol 17: 1168–1174, 2006. 
71. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G.: Meta-analysis: Effect of hepatitis 
C virus infection on mortality in dialysis. Aliment Pharmacol Ther 20: 1271–1277, 2004.  
72. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G.: Hepatitis C virus antibody status 
 
83 
 
 
 
and survival after renal transplantation: Meta-analysis of observational studies. Am J 
Transplant 5: 1452–1461, 2005. 
73. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjerston SW, 
Kopple JD, Greenland S.: Hepatitis C virus and death risk in hemodialysis patients. J Am Soc 
Nephrol 18: 1584–1593, 2007. 
74. Pereira BJ, Natov SN, Bouthot BA, Murthy BVR, Ruthhazer R, Schmid CH, Levey AS.: 
Effects of hepatitis C infection and renal transplantation on survival in end-stage renal 
disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 53: 1374–1381, 
1998.  
75. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ.: Risk of death among chronic 
dialysis patients infected with hepatitis C virus. Am J Kidney Dis 32: 629–634, 1998. 
76.Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, Held PJ, Port 
FK.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting 
transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725–1730, 
1999.  
77. Pereira BJ, Wright TL, Schmid CH, Levey AS.: The impact of pretransplantation hepatitis 
C infection on the outcome of renal transplantation. Transplantation 60: 799–805, 1995.  
78. Batty DS, Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC.: Hepatitis C virus 
seropositivity at the time of renal transplantation in the United States: Associated factors and 
patient survival. Am J Transplant 1: 179–184, 2001. 
79. Pol S, Romeo R, Zins B, Driss F, Lebkiri B, Garnot F, Berthelot P, Brechot C.: Hepatitis 
C virus RNA in anti-HCV positive hemodialyzed patients: Significance and therapeutic 
implications 
80.Effect of Kidney Transplantation on Outcomes among Patients with Hepatitis C.David 
Roth, Jeffrey J. Gaynor,† K. Rajender Reddy.JASN. 
81. Katherine Barraclough1.Life-threatening adenovirus infection in a kidney transplant 
recipient. NDT Plus (2009) 2: 250–253 
82.K. Sujeet1, B. Vasudev1, P. Desai1. Acute kidney injury requiring dialysis secondary to 
adenovirus nephritis in renal transplant recipient. Transplant Infectious Disease . ISSN 1398-
2273. 
83.Awadalla Y, Randhawa P, Ruppert K, Zeevi A, DuquesnoyRJ: HLA mismatching 
increases the risk of BK virus nephropathyin renal transplant recipients. Am J Transplant 
4:1691–1696, 2004. 
84.BK Virus Nephritis after Renal Transplantation.Aaron Dall and Sundaram Hariharan. Clin 
J Am Soc Nephrol 3: S68–S75, 2008. 
85.Prosser S, Hariharan S: Pathogenesis of BK virus infectionafter renal transplantation. Exp 
Rev Clin Immunol 2: 833–837, 2006. 
 
84 
 
 
 
86. MAGALI GIRAL,1 GIOVANI PASCUARIELLO,1 GEORGES KARAM, MARYVONNE HOURMANT.Acute graft 
pyelonephritis and long-term kidneyallograft outcome Kidney International, Vol. 61 (2002), 
pp. 1880–1886 
87.Lyerová L, Lácha J, Skibová J, et alUrinary tract infection in patients with urological 
complications after renal transplantation with respect to long-term function and allograft 
survival. Ann Transplant 2001;6:19-20. 
 
 
 
 
 
 
 
 
 
  
 
